Editorial Commentary
Paradigm shift in local consolidative therapy for oligometastatic non-small cell lung cancer: a meta-analysis
Abstract
Should patients with oligometastatic non-small cell lung cancer (NSCLC) undergo local consolidative therapy (LCT)? That was the question posed by Gomez and colleagues, who should be congratulated on their randomized controlled trial originally published in 2016 in Lancet Oncology (1).